


Novartis partners with TB alliance

21 August 2014 | News | By BioSpectrum Bureau



Singapore: Novartis has partnered with Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at Novartis Institutes for Tropical Diseases (NITD).

According to the World Health Organization, there are more than 8.6 million cases of tuberculosis each year, with more than 1.3 million deaths reported annually. TB is a global disease, but has its deadliest impact in resource-poor countries. Current therapies for TB require 6-30 month dosing regimes and there are increasingly drug resistant strains of TB emerging.

"TB is one of the scourges of the developing world and new medicines are desperately needed to combat its continued spread," said Mr Mark C Fishman, president of Novartis Institutes for BioMedical Research. "TB Alliance is well placed to take our discoveries and compounds through development for the benefit of patients with TB."

"Our long-standing partnership with Novartis gives us confidence in the scientific underpinnings of the TB portfolio," says Mr Mel Spigelman, president and CEO, TB Alliance. "We look forward to advancing the most promising compounds into the clinic to meet the urgent need for new TB treatments."

Under the terms of agreement, NITD will fully transfer its TB research and development program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval and distribution of compounds in the portfolio. Included is a novel class of drugs called indolcarboxamides that are active against drug sensitive and multi-

resistant strains of TB. One of these preclinical compounds NITD304, blocks MmpL3, a protein essential for the TB bacterium's survival.